CalciMedica is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for life-threatening inflammatory diseases with high unmet need. CalciMedica’s proprietary technology targets the inhibition of CRAC channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are currently no approved therapies.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
CalciMedica Acute Pancreatitis Clinical Experts Event
Listen to the Webcast